Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2022-02-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司独立董事关于关联交易事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a pre-approval opinion from independent directors regarding a related-party transaction involving a lease agreement between a subsidiary and a company controlled by the actual controller of the listed company. It references compliance with stock exchange listing rules and corporate governance regulations. The document is short (1005 characters) and focuses on governance and approval of a specific transaction rather than financial results or report publication. It is not an annual or interim report, nor an earnings release or audit report. It is not a voting result or a proxy solicitation. The content fits best under Board/Management Information (MANG) as it concerns board-level approval and governance of a related-party transaction.
2022-02-18 Chinese
中源协和细胞基因工程股份有限公司关于控股子公司与上海延藜生物技术有限公司签署房地产租赁合同暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving a real estate lease contract between the company's subsidiary and an affiliated company controlled by the same ultimate controller. It includes specifics about the lease terms, pricing, related party relationships, board approvals, and the impact on the company. There is no indication that this is a financial report, earnings release, or management discussion. It is a regulatory announcement about a significant related-party transaction, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Board/Management Information. The document length and content confirm it is not a mere report publication announcement or certification. Therefore, the classification is Regulatory Filings (RNS).
2022-02-18 Chinese
中源协和细胞基因工程股份有限公司股东减持计划实施期间届满暨集中竞价减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding the completion of a shareholder's planned reduction in shareholding through centralized bidding. It details the shareholder's initial holdings, the planned reduction amount, the actual shares reduced, and the current holdings post-reduction. The document includes specific dates, share quantities, percentages, and prices related to the share reduction. This type of document is a notification about a major shareholder's change in share ownership levels, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short (1364 characters) and it is not a report or financial statement but an announcement of shareholding changes.
2022-02-07 Chinese
中源协和细胞基因工程股份有限公司2021年年度业绩预盈公告
Earnings Release Classification · 95% confidence The document is titled as an "年度业绩预盈公告" which translates to "Annual Performance Profit Forecast Announcement" for the year 2021. It provides preliminary profit estimates, including net profit attributable to shareholders and adjustments for non-recurring gains/losses. It explicitly states that the forecast is unaudited and that final audited data will be disclosed in the formal annual report. The document length is short (1329 characters) and it serves as a profit warning or earnings forecast rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal year before the full annual report is published.
2022-01-28 Chinese
中源协和细胞基因工程股份有限公司关于5%以上股东减持至5%以下权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder's reduction of holdings from above 5% to below 5%. It details the shareholder's name, share quantities before and after the transaction, and confirms no change in controlling shareholders. The document references a "简式权益变动报告书" (Simplified Equity Change Report) filed with the Shanghai Stock Exchange. This type of announcement corresponds to notifications about changes in major shareholdings, specifically when crossing significant ownership thresholds. The document length is short (1690 characters) and is a direct announcement of the shareholding change, not a full report or financial statement. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2022-01-19 Chinese
中源协和细胞基因工程股份有限公司关于增资上海中源济生细胞科技有限公司暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a capital increase (增资) involving the company and its subsidiaries/related parties. It includes specifics about the investment amounts, shareholding percentages before and after the capital increase, the parties involved, the purpose and impact of the transaction, and the approval process by the board. The content focuses on financing activities and changes in the capital structure of a subsidiary company. There is no indication that this is a full financial report, audit report, or regulatory filing unrelated to financing. The document is not a brief announcement of a report publication but a substantive update on a capital transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (5838 characters) supports it being a full announcement rather than a brief notice.
2022-01-19 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.